Amicus Therapeutics, Inc. (NASDAQ: FOLD) is engaged in the development of treatments for orphan illnesses. It has developed molecules called chaperones used for the management of lysosomal storage diseases (LSDs). The molecules may provide a therapy for Fabry, Pompe, Gaucher and other LSDs. They are developed to increase the activity of a patient’s enzyme. They may strengthen enzymes in combination with enzyme replacement therapy........